Table 2.
Characteristics | MPO-ANCA nephritis with UIP pattern | IPF | p-value |
---|---|---|---|
Patients | 31 | 32 | |
Age, years | 74 (58–88) | 70 (58–87) | 0.083 |
Male | 16 | 29 | 0.0021 |
Smoking history | |||
Never/former or current | 16/15 | 6/26 | 0.0068 |
Respiratory symptoms | |||
Cough | 19 | 16 | 0.37 |
Dyspnea | 12 | 18 | 0.16 |
None | 9 | 6 | 0.34 |
Serological testing | |||
LDH, U/L | 225.5 ± 64.9 | 236.2 ± 45.1 | 0.35 |
KL-6, IU/mL | 1298 ± 914.8 | 1341 ± 853.5 | 0.73 |
Treatment | |||
None | 2 (6.5) | 0 (0.0) | |
Immunosuppressive agents | 28 (90.0) | 0 (0.0) | |
Antifibrotic agents | 1 (3.2) | 32 (100.0) | |
nintedanib | nintedanib n = 14 | ||
300 mg/day | 300 mg/day n = 4 | ||
200 mg/day n = 10 | |||
pirfenidone n = 18 | |||
1800 mg/day n = 3 | |||
1200 mg/day n = 11 | |||
600 mg/day n = 4 |
Data are presented as n, median (range), mean ± standard deviation, or n (%)
MPO-ANCA nephritis myeloperoxidase anti-neutrophil cytoplasmic antibody-related nephritis, UIP usual interstitial pneumonia, IPF idiopathic pulmonary fibrosis, LDH lactate dehydrogenase, KL-6 Krebs von den Lungen-6